Die Suchmaschine für Unternehmensdaten in Europa

EU-Förderung (15,5 Mio. €): Bessere Bekämpfung und Behandlung von immunvermittelten Krankheiten durch die Erforschung des Universums der mikroumweltbelasteten Gewebesignaturen und deren Korrelationen … Hor 01.01.2020 EU-Rahmenprogramm für Forschung und Innovation "Horizont"

Auf einen Blick

Text

Bessere Bekämpfung und Behandlung von immunvermittelten Krankheiten durch die Erforschung des Universums der mikroumweltbelasteten Gewebesignaturen und deren Korrelationen in flüssigen Biopsien

Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enormous heterogeneity with regard to disease outcome and response to targeted therapies, which currently cannot be adequately anticipated to tailor individual patient management. Hence, mechanistic understanding of this heterogeneity and biomarkers predictive for disease control and therapy response over time are important prerequisites of a future precision medicine in IMIDs. ImmUniverse has been formed as a European transdisciplinary consortium to tackle these unmet needs and to understand the role of the crosstalk between tissue microenvironment and immune cells in disease progression and response to therapy of two different IMIDs: ulcerative colitis and atopic dermatitis. Following this unique cross-disease approach ImmUniverse will fill the gap and the limitations of current studies, which do not systematically compare the complex interactions between recirculating immune cells and the respective tissue microenvironment. The consortium will combine analysis of tissue-derived signatures with “circulating signatures” detectable in liquid biopsies, employing state-of-the-art profiling technologies corresponding to multi-Omics datasets. The project will also bring diagnostics in IMID to a new level by implementing disruptive non-invasive liquid-biopsy methodology in combination with novel, validated circulating biomarker assays which are expected to improve diagnosis, inform early in the clinical course on disease severity and progression and enable treatment response monitoring. The identified signature will be validated to monitor state/progression and response to therapy in prospective observational cohorts. Realization of these objectives will result in improvement of patient management, lead to increased patient well-being and will significantly reduce the socioeconomic burden of these diseases.


Geförderte Unternehmen:

Firmenname Förderungssumme
Aarhus Universitet 174.488 €
Aarhus Universitetshospital 353.596 €
AIT Austrian Institute OF Technology GmbH 2.131.236 €
Centre Hospitalier Regional Universitaire Nancy 103.784 €
Christian-Albrechts-Universitaet ZU Kiel 2.915.000 €
Eli Lilly and Company Ltd. 0,00 €
Erasmus Universitair Medisch Centrum Rotterdam 105.000 €
Eurice European Research AND Project Office GmbH 704.063 €
European Federation OF Asthma &Allergy Associations Ideell Forening 50.250 €
Forum des Patients Europeens 11.781,25 €
Glaxosmithkline Research & Development Ltd. 0,00 €
Humanitas Mirasole S.p.A. 0,00 €
Information Technology FOR Translational Medicine (Ittm) SA 400.501 €
International Federation OF Crohn'S AND Ulcerative Colitis Associations 50.313 €
Istituto Superiore Di Sanita 502.989 €
Joanneum Research Forschungsgesellschaft mbH 894.909 €
Katholieke Universiteit Leuven 516.693 €
Ludwig-Maximilians-Universitaet Muenchen 392.975 €
Novartis Pharma AG 0,00 €
Pfizer Ltd. 0,00 €
Sanofi-Aventis Deutschland GmbH 0,00 €
Scuola Superiore Di Studi Universitari E Di Perfezionamento S Anna 360.000 €
Stichting Amsterdam UMC 633.048 €
Stichting Radboud Universitair Medisch Centrum 1.096.421 €
Stichting Radboud Universiteit 0,00 €
The Chancellor Masters and Scholars of the University of Cambridge 445.294 €
Universitaet ULM 210.000 €
Universita Humanitas 1.925.508 €
Universita Vita-Salute SAN Raffaele 96.313 €
Universite Du Luxembourg 780.939 €
VIB VZW 644.900 €

Quelle: https://cordis.europa.eu/project/id/853995

Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.